Connect with us

Medical Research

Harvest One’s Satipharm Phase 2 Clinical Trials of CBD Gelpell Shows Positive Epilepsy Results

Denis

Published

on

Harvest One’s Satipharm Phase 2 Clinical Trials of CBD Gelpell Shows Positive Epilepsy Results

In a recent press release, early-entry global cannabis company, Harvest One revealed that the Phase 2 clinical trials of its CBD Gelpell® has shown significant results.

The Satipharm CBD Gelpell® is described as housing full spectrum CBD hemp extract within seamless Gelpell® gelatine beads. The latter has been done to increase CBD’s bioavailability and the body’s absorption levels of cannabinoids. This is made possible due to the invisible protective layer that the beads provide to the cannabinoids against heat, light and oxidation.

As for the results of study, they have since been published in Epilepsy & Behavior, where the study looked closely at the CBD ingestion for Treatment Resistant Epilepsy (TRE) in patients with severe conditions. Interestingly, it has been concluded that Satipharm CBD capsules are safe and effective in reducing the frequency of seizures experienced among children with “refractory, or treatment-resistant, epilepsy.”

To put things into perspective, within a 12-week span, seizures reduced by 82% on a monthly basis, with 73% rated as “very much improved/improved” in their overall condition, 82% rated as “very much reduced/reduced,” and two patients becoming fully seizure-free within the first 5 weeks of treatment. The sentiments are expressed using the Caregiver Global Impression of Improvement Scale.

The CEO of Harvest One, Grant Froese, is happy to see such promising results from the Phase 2 clinical trials, adding that moving forward more will be done to “focus on the best in class health, wellness, and self-care products at Harvest One.”

He also mentioned that he’s anticipating an increase in demand for Gelpell® upon the complete legalization of cannabis worldwide.

As per Professor Uri Kramer, Director of Pediatric Epilepsy Service and Lead Investigator, “These results compare favourable to other similar studies of cannabidiol,” adding that the “significant reductions in seizure frequency while demonstrating satisfactory safety and tolerability profile […] have the potential to be a life-altering event for these patients and their families.”

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

Join Us On Facebook

Advertisement

Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?

Advertisement